Stockscreener 앱 받기
1,027.51
1.80%
18.13
시장 영업 전:
1033.36
5.85
+0.57%
전일 마감가:
$1,009.38
열려 있는:
$1008.76
하루 거래량:
3.24M
Relative Volume:
0.86
시가총액:
$919.64B
수익:
$59.42B
순이익/손실:
$18.41B
주가수익비율:
50.82
EPS:
20.2197
순현금흐름:
$6.44B
1주 성능:
+1.70%
1개월 성능:
+0.96%
6개월 성능:
+26.54%
1년 성능:
+31.34%
1일 변동 폭
$1,003.50
$1,028.90
1주일 범위
$977.12
$1,031.56
52주 변동 폭
$623.78
$1,111.99
일라이 릴리 Stock (LLY) Company Profile
명칭
Lilly Eli Co
전화
(317) 276-2000
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
LLY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,027.51 | 903.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
211.58 | 505.98B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.32 | 395.86B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.57 | 253.97B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.30 | 245.75B | 63.90B | 19.05B | 13.05B | 7.5596 |
일라이 릴리 Stock (LLY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-11-10 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 재확인 | BMO Capital Markets | Outperform |
| 2025-10-14 | 업그레이드 | Erste Group | Hold → Buy |
| 2025-09-17 | 다운그레이드 | Berenberg | Buy → Hold |
| 2025-08-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2025-08-18 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-09-13 | 재개 | Citigroup | Buy |
| 2024-08-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-02-21 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2024-02-16 | 재확인 | Morgan Stanley | Overweight |
| 2023-12-21 | 다운그레이드 | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-20 | 재개 | UBS | Buy |
| 2023-08-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-26 | 재확인 | Citigroup | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-24 | 재확인 | BofA Securities | Buy |
| 2023-05-24 | 재확인 | UBS | Buy |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-15 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-09-22 | 업그레이드 | UBS | Neutral → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-03-10 | 개시 | Daiwa Securities | Outperform |
| 2022-01-21 | 업그레이드 | DZ Bank | Hold → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-16 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-16 | 재확인 | BofA Securities | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2021-09-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-05 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-06-24 | 재확인 | Cantor Fitzgerald | Overweight |
| 2021-01-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-12-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-09-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2019-12-18 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-04-24 | 업그레이드 | Edward Jones | Hold → Buy |
| 2019-04-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-03-12 | 개시 | JP Morgan | Overweight |
| 2019-01-23 | 개시 | UBS | Buy |
| 2018-11-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-10-01 | 재확인 | SunTrust | Buy |
| 2018-09-26 | 재개 | JP Morgan | Overweight |
모두보기
일라이 릴리 주식(LLY)의 최신 뉴스
V. M. Manning & CO. Inc. Invests $875,000 in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company (NYSE:LLY) Stock Unloaded Rep. Julie Johnson - MarketBeat
Eli Lilly price target raised to $1,145 from $951 at Goldman Sachs - TipRanks
Eli Lilly and Company $LLY Shares Purchased by NWF Advisory Services Inc. - MarketBeat
Silicon Valley Capital Partners Boosts Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Purchased by SevenBridge Financial Group LLC - MarketBeat
Orion Porfolio Solutions LLC Has $39.62 Million Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly & Co: Strategic Initiatives and Promising Market Opportunities Drive Buy Rating - TipRanks
Thrivent Financial for Lutherans Acquires 52,783 Shares of Eli Lilly and Company $LLY - MarketBeat
MASTERINVEST Kapitalanlage GmbH Acquires New Holdings in Eli Lilly and Company $LLY - MarketBeat
Kentucky Retirement Systems Insurance Trust Fund Trims Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly Just Delivered Fantastic News to Investors - Finviz
Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade) (NYSE:LLY) - Seeking Alpha
Cim Investment Management Inc. Has $3.12 Million Stake in Eli Lilly and Company $LLY - MarketBeat
American Trust Buys 3,644 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly (LLY) Expands Mounjaro Use to Younger Patients in Euro - GuruFocus
Eli Lilly’s Retatrutide Study: A New Hope for CKD Treatment? - TipRanks
Eli Lilly’s New Study on Obesity Drug LY4167586: What Investors Need to Know - TipRanks
Eli Lilly’s New Study on LY3549492: A Potential Breakthrough in Obesity Treatment - TipRanks
Eli Lilly Completes Phase 1 Study of Eloralintide for Obesity in China - TipRanks
Eli Lilly Weight Loss Drug Shows Impressive Results in Phase 3 Trial - InsideHook
2 Predictions for Novo Nordisk in 2026 - The Motley Fool
Eli Lilly Stock (LLY) News, Forecasts and Analyst Outlook — Retatrutide Breakthrough, Orforglipron FDA Timeline, and a $6B Manufacturing Bet (Dec. 14, 2025) - ts2.tech
Notable healthcare headlines for the week: CVS, Eli Lilly and Novartis in focus - MSN
Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025) - ts2.tech
Liontrust Investment Partners LLP Grows Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Rexford Capital Inc. Purchases Shares of 1,488 Eli Lilly and Company $LLY - MarketBeat
Public Sector Pension Investment Board Lowers Position in Eli Lilly and Company $LLY - MarketBeat
Castleark Management LLC Reduces Stock Position in Eli Lilly and Company $LLY - MarketBeat
Brick & Kyle Associates Purchases 1,700 Shares of Eli Lilly and Company $LLY - MarketBeat
Advisory Services Network LLC Buys 1,351 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial - MSN
Eli Lilly’s Stock Sets a New Industry Standard - AD HOC NEWS
Has Lilly’s Obesity Drug Boom Pushed Its 2025 Valuation Too Far? - simplywall.st
Eli Lilly: The Right Long-Term Strategy - Seeking Alpha
Eli Lilly and Company $LLY is Banque Transatlantique SA's 10th Largest Position - MarketBeat
Blue Capital Inc. Takes Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Sold by AQR Capital Management LLC - MarketBeat
Eli Lilly and Company $LLY Shares Sold by Ameriprise Financial Inc. - MarketBeat
Adage Capital Partners GP L.L.C. Raises Stake in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly Further Cements Itself As The King Of Weight Loss (NYSE:LLY) - Seeking Alpha
Why the Market Dipped But Eli Lilly (LLY) Gained Today - sharewise.com
Eli Lilly and Company (NYSE:LLY) Shares Up 1.8%Here's Why - MarketBeat
Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next - ts2.tech
Clinical trials reveal promising results for new Eli Lilly drug - NewsNation
What's Going On With Eli Lilly Stock Friday?Eli Lilly (NYSE:LLY) - Benzinga
Eli Lilly to Build $6-Billion Alabama Facility - AdvancedManufacturing.org
Moody’s affirms Eli Lilly’s Aa3 rating, outlook revised to positive By Investing.com - Investing.com Nigeria
Eli Lilly (LLY) Reports Promising Results from Phase 3 EMBER-3 S - GuruFocus
Eli Lilly announces updated results from Phase 3 EMBER-3 study of Inluriyo - TipRanks
Exclusive: FDA leaders pushed to cut Lilly weight-loss pill review time - Reuters
일라이 릴리 (LLY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.75%
0.29%
자본화:
|
볼륨(24시간):